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Prediabetes is diagnosed in individuals whose plasmaglucose levels donotmeet the criteria for diabetes but
are too high to be considered normal (1). Such persons are
considered to be at increased risk for the subsequent de-
velopment of cardiovascular disease (CVD) and diabetes.
Although the initiation of interventions and frequent fol-
low-up are recommended, the presence of prediabetes is
considered a risk factor rather than a clinical entity in its
own right (1). Prediabetes is most often detected as a sec-
ondary considerationwhen a clinician performs one of the
three recommended tests to diagnose diabetes. Hence, the
diagnostic tests for diabetes/prediabetes include the mea-
surement of glycated hemoglobin (HbA1c), fasting
plasma glucose (FPG) or the 2-hour glucose concentration
after a 75-g oral glucose tolerance test (OGTT).
Recent data suggest that prediabetes is present in 38%
ofUS adults (2). Because somany individuals appear to be
afflicted with prediabetes, it is important to examine the
consequences of this risk state and consequently whether
the future risks it portends areworthy of expending public
or health plan resources at a time when health care ex-
penditures are already considerable.
The history of prediabetes
In 1997, the American Diabetes Association (ADA) es-
tablished the entity of impaired fasting glucose (IFG) as a
prediabetes state defined as a FPG concentration of 110–
125 mg/dL (6.1–6.9 mmol/L) (3). This criterion was ad-
opted by the World Health Organization (WHO) (4). In
2003, the ADA lowered the criterion for IFG to 100–125
mg/dL (5.6–6.9 mmol/L) (5). This decision was based on
the observation that many fewer persons with IFG subse-
quently developed diabetes than those whose prediabetes
was diagnosed as impaired glucose tolerance (IGT) by a
2-hour glucose value on an OGTT of 140–199 mg/dL
(7.8–11.0 mmol/L) (5, 6). Lowering the criterion for IFG
to 100–125 mg/dL (5.6–6.9 mmol/L) enabled a similar
number of people with IFG and IGT to subsequently de-
velop diabetes, although different people might fall into
the different diagnostic categories of prediabetes (5). The
WHO did not adopt this new criterion for IFG (7).
In 2008, an Invited Expert Panel recommended that the
diabetes community consider diagnosing diabetes with an
HbA1c level of 6.5% or greater (48 mmol/mol), a value
just under 3 SD above the National Health and Nutrition
Examination Survey population mean. They also sug-
gested that a HbA1c level of 6.0–6.4% (42–48 mmol/
mol) (2 SD above the population mean) mandated fur-
ther testing and closer follow-up (8). The ADA, the
European Association for the Study of Diabetes, and the
International Diabetes Federation then convened an In-
ternational Expert Committee and agreed with the rec-
ommendation that, based on the association of diabetic
retinopathy, diabetes could be diagnosed with a HbA1c
level of 6.5% or greater (48 mmol/mol), if confirmed (9).
They further argued that because of the continuum of risk
in the subdiabetic glycemic range, dichotomous subdia-
betic classifications (eg, prediabetes) are inappropriate
and should not be created to define a specific at-risk group
(9). Thus, they recommended that, given the lack of an
identifiable threshold at which prevention efforts should
be implemented, people with HbA1c levels of 6.0% or
greater (42 mmol/mol), which is obviously near the diag-
nostic threshold, should be monitored more closely and
should be considered candidates for an intervention to
prevent diabetes (9).
The ADA formally accepted the recommendation for
the diagnosis of diabetes but went further by adopting an
HbA1c criterion for prediabetes of 5.7%–6.4% (39–48
mmol/mol) (1). The lower bounds of the HbA1c criterion
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for prediabetes was apparently based on the cross-sec-
tional values of the 2005–2006 National Health and
Nutrition Examination Survey population that were fed
into models that estimated the risk for developing dia-
betes and CVD (10), rather than on prospective studies.
The WHO accepted the ADA recommendation on the
HbA1c criterion for diagnosing diabetes but believed
that that there was insufficient evidence to make any
recommendations for values less than 6.5% (48 mmol/
mol) (11).
As expected, using the ADA definition for prediabetes,
the number of Americans potentially diagnosed with the
condition is enormous, nearly 40% of the adult popula-
tion (2).Gregg et al (12)havepointedout that the less strict
the criteria used to identify prediabetes, the more people
will be eligible for an intervention, and therefore, more
individualsmaybe helpedbut at the cost of a large number
forwhomthe interventionwouldnot benecessarybecause
they were not destined to develop diabetes. Conversely,
the more strict the criteria for prediabetes, the fewer the
individuals who will be eligible for an intervention, but
there would be greater economic efficiency in that more
cases of diabeteswouldbedelayedper individual receiving
the intervention.
Given the trade-offs identified by Gregg et al (12), the
observation that achieving diabetes prevention in clinical
trials (13–15) was expensive, and that sustainable weight
loss has been very difficult to achieve in community set-
tings (16, 17), all suggest that considerable resources
would be necessary to prevent/delay the development of
diabetes in a population. Moreover, and at the least
before initiating nationwide programs, we should crit-
ically examine the evidence that prediabetes has clinical
merit. Specifically, the question is whether an FPG of
100–109 mg/dL (5.6–6.0 mmol/L) or a HbA1c of 5.7–
5.9 (39–41 mmol/mol) or even an FPG of 110–125
Table 1. Relationship Between Subdiabetic Hyperglycemia (Glucose Concentrations, FPG, mg/dL [mmol/L]) and
Incident CVD
Reference Population Follow-Up, y Outcomes Results
26 n  2363
Dutch, aged 50–75 y
8 CVD death Referent 94 (5.2)
94–99 (5.2–5.5), HR 0.82
100–109 (5.6–6.0), HR 0.52a
110–125 (6.1–6.9), HR 1.07
27 n  2789
Chinese, Malay, and Asian Indian males
8 Ischemic heart disease 100–109 (5.6–6.0), HR 1.13
110–125 (6.1–6.9), HR 1.51
28 n  36 386
Chinese aged 40 y
11 CVD death 100–109 (5.6–6.0), RR 1.00
110–125 (6.1–6.9), RR 1.51
29 n  2763
Postmenopausal US women with CHD
6.8 Nonfatal CHD
CHD deaths
Any CHD event
100–109 (5.6–6.0), HR 0.81
110–125 (6.1–6.9), HR 1.56a
100–109 (5.6–6.0), HR 1.11
110–125 (6.1–6.9), HR 1.06
100–109 (5.6–6.0), HR 0.90
110–125 (6.1–6.9), HR 1.37a
Stroke/TIA 100–109 (5.6–6.0), HR 1.30
110–125 (6.1–6.9), HR 1.35
Any CVD event 100–109 (5.6–6.0), HR 0.90
110–125 (6.1–6.9), HR 1.21
30 Framingham Offspring 15 4-y event rates
n  2163 women and 1895 men Women Men
CHD 100–109 (5.6–6.0) OR 1.4 0.9
110–125 (6.1–6.9) OR 2.5a 0.9
CVD 100–109 (5.6–6.0) OR 1.1 1.1
110–125 (6.1–6.9) OR 2.1a 1.0
31 n  384 795 Koreans aged 20 y 10 CVD 100–109 (5.6–6.0), HR 1.02
110–125 (6.1–6.9), HR 1.05a
32 DECODE Study
n  29 714 aged 30–89 y
11 CVD death Referent 81–109 (4.5–6.1)
110–125 (6.1–6.9), HR 1.6a
33 n  2651 Japanese 40 y old 7 CVD death Referent 110 (6.1)
110–125 (6.1–6.9), HR 0.97
34 DECODA Study
n  6817 Japanese and Asian Indian
5–10 CVD death Referent 110 (6.1)
110–125 (6.1–6.9), HR 1.35
35 ARIC Study
n  1328 aged 45–64 y
8–10 CHD event Referent 94 (5.2) first quintile in people
without diabetes
94 to 99 (5.2 to 5.5), RR 1.05
99 to 104 (5.5 to 5.8), RR 1.13
104 to 110 (5.8 to 6.1), RR 1.17
110 (6.1), RR 1.06
Abbreviations: ARIC, Atherosclerosis Risk in Communities; DECODA, Diagnostic Criteria in Asia; DECODE, Diagnostic Criteria in Europe; EPIC,
European Prospective Investigation Into Cancer; HR, hazard ratio; n, number of persons followed up (either without diabetes at baseline if those
numbers provided or entire population tested if not); OR, odds ratio; RR, relative risk; TIA, transient ischemic attack. Referent is less than 100 (5.6)
unless otherwise stated.
a P  .05.
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mg/dL (6.1–6.9 mmol/L) or a HbA1c of 6.0–6.4
(42–48 mmol/mol) represent sufficient risk of a clinical
adverse outcome, ie, a CVD event or a microvascular
complication, after prediabetes developed into diabe-
tes, that would merit an intervention. (Since the OGTT
is rarely used in nonpregnant individuals [18], we only
evaluate the benefit of identifying those with prediabe-
tes by the FPG or HbA1c criteria.)
The papers on which this Position Statement is based
were identified in a comprehensive review of publications
from 2003 through 2015. The ADA recommended the
lower glucoseboundsofprediabetes in2003and the lower
HbA1cboundsofprediabetes in2011.Only incident stud-
ies that separately tracked the association with CVD and
the development of diabetes within the lower and upper
bounds of the ADA definitions of prediabetes in the same
population from 2003 were reviewed. This limited the
number of studies analyzed in this manuscript because the
vast majority related to this subject simply tracked sub-
jects with IGT or individuals who fulfilled the entire def-
initions of the ADA or the WHO. Since 1995, the first
author has published 20 papers on screening for and di-
agnosing diabetes and has kept an extensive file in this
area.Articles in this file from2003 through2015 and their
bibliographies were reviewed, and 31 papers that fulfilled
the criteriamentionedabovewere identified and thuswere
included in this Position Statement.
Can we prevent CVD by treating prediabetes?
Although incident CVD will vary, depending on the
intrinsic risk in the population being evaluated and
the duration of follow up, comparisons within a study
are valid. Among studies using incident CVD as the out-
come, the evidence that the glycemia of prediabetes is an
independent risk factor for CVD is not very strong.When
risk factors for CVD were taken into account in persons
with IFG, there was no increase in CVD with prediabetes
diagnosed with either FPG concentrations of 110–125
mg/dL (6.1–6.9 mmol/L) (19, 20) or 100–125 mg/dL
(5.6–6.9 mmol/L) (21–23). Similarly, in meta-analyses,
adding FPG (24) or HbA1c (25) levels to the other risk
factors did not improve the prediction for CVD.
We examined associations in different populations of
various outcomes of incident CVD with preexisting gly-
cemia, again with other risk factors for CVD taken into
account. The associations as defined by FPG criterion are
shown inTable 1. A cohort is defined as a separate defined
population (eg, ethnic group, sex) inwhoma specificCVD
outcome (eg, coronary heart disease [CHD], stroke, CVD
mortality, etc) was tracked. There was no increase in in-
cident CVD with FPG concentrations of 100–109 mg/dL
(5.6–6.0 mmol/L) in 13 cohorts compared with individ-
uals with lower values. With FPG concentrations of
110–125 mg/dL (6.1–6.9 mmol/L), 11 cohorts showed
no significant association, whereas six did (Figure 1).
Studies evaluating HbA1c levels compared values
mostly of 5.5%–5.9% (37–41 mmol/mol) and those of
6.0%–6.4% (42–48 mmol/mol) with control values of
less than 5.5% (37 mmol/mol) (Table 2). With HbA1C
levels of 5.5%–5.9% (37–41 mmol/mol), there was no
significant association in nine cohorts, whereas there was
in three.WithHbA1c levels of 6.0%–6.4%(42–48mmol/
mol), nine cohorts showed no significant association,
whereas nine did (Figure 1).
Treating prediabetes to prevent diabetes
In contrast to the CVD outcomes of prediabetes, there
is very good evidence that the glycemia of prediabetes is a
risk factor for the development of diabetes. However,
there is no threshold and the increased risk begins at FPG
concentrations of 82–87 mg/dL (4.6–4.8 mmol/L) (43–
45). The risk is curvilinear and increases faster the nearer
the FPG concentration approaches 126mg/dL (7.0mmol/
L), the criterion for diagnosing diabetes. As with incident
CVD, the absolute incident rate of developing diabetes
depends on the intrinsic risk of the population being
examined, the duration of follow-up, but in this case,
also the criteria used for the diagnosis of diabetes.
Within each study though, a comparison of the lower
bounds with the higher bounds of the criteria for pre-
diabetes is valid.
There was a 4.6-fold increase (range 2.1–8.8) in the
development of diabetes in individuals meeting the 110–
Figure 1. Predictive value of the lower and upper bounds of the
criteria for prediabetes on incident CVD. A cohort is a separate defined
population (eg, ethnic group, sex) in which a specific CVD outcome
(eg, CHD, stroke, CVD mortality, etc) was tracked. Clear bar,
association not statistically different from control group; striped bar,
association statistically different from control group. Control groups
had the following: FPG less than 100 mg/dL (5.6 mmol/L); HbA1c less
than 5.5% (37 mmol/mol).
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125 mg/dL (6.1–6.9 mmol/L) criterion compared with
those whose FPGwas 100–109mg/dL (5.6–6.0 mmol/L)
(Table 3 and Figure 2). Similarly, there was a 3.7-fold
increase (range 2.0–6.5) in the development of diabetes in
individuals with HbA1c levels of 6.0% or greater (42
mmol/mol) compared with those with HbA1c levels of
5.5%–6.0% (37–42 mmol/mol) (Table 4 and Figure 2).
Discussion
Although the evidence that prediabetes is an indepen-
dent risk factor for CVD is weak, especially for FPG of
100–109 mg/dL (5.6–6.0 mmol/L) (Table 1) and HbA1c
less than 6.0% (42 mmol/mol) (Table 2), there is strong
evidence for a progressive curvilinear increasing risk of
glycemia for the development of diabetes (Tables 3 and 4).
At FPG levels of 110–125 mg/dL (6.1–6.9 mmol/L) or
HbA1c levels of 6.0%–6.4% (42–48 mmol/mol), there is
about a 4-fold increase in the risk of developing diabetes
comparedwith lower FPG levels of 100–109mg/dL (5.6–
6.0 mmol/L) or HbA1c levels of 5.5–5.9% (37–41
mmol/mol).
In addition to lifestyle interventions for those diag-
nosed with prediabetes, based on the results of the Dia-
betes Prevention Program consideration of metformin
therapy for obese individuals younger than 60 years of age
has been suggested (59). When metformin was discontin-
Table 2. Relationship Between Subdiabetic Hyperglycemia (HbA1c Levels, % [mmol/mol]) and Incident CVD
Reference Population Follow-Up, y Outcomes Results
23 ARIC Study 14 Referent 5.0–5.4 (31–36)
n  10 613; aged 45–64 y CHD 5.0 (31), HR 0.96
5.5 to 6.0 (37 to 42), HR 1.23a
6.0 to 6.5 (42 to 48), HR 1.78a
Ischemic stroke 5.0 (31), HR 1.09
5.5 to 6.0 (37 to 42), HR 1.17a
6.0 to 6.5 (42 to 48), HR 2.22a
36 EPIC Study
n  4337 men and 5346
women aged 45–79 y
6 Referent 5.0 (31)
Women Men
CHD events 5.0–5.4 (31–36) RR 0.96 1.56a
5.5–5.9 (37–41) RR 1.04 2.00a
6.0–6.4 (42–48) RR 2.29* 2.13a
CVD events 5.0–5.4 (31–36) RR 0.89 1.23
5.6–5.9 (38–41) RR 0.98 1.56a
6.0–6.4 (42–48) RR 1.63 1.79a
37 n  3073 Japanese A-bomb
survivors
8.8 CVD death Referent 5.5 (37)
5.5 to 6.0 (37 to 42), HR 0.99
6.0 to 6.5 (42 to 48), HR 1.63a
38 Women’s Health Study
n  26 443 aged 45 y
10.1 CVD events Referent 5.0 (31)
5.0–5.4 (31–36), RR 0.9
5.5–5.9 (37–41), RR 1.2
6.0–6.4 (42–48), RR 1.6
39 n  6406 Japanese
aged 30–79 y
12.7 Referent 5.9 (41)
CVD 6.0–6.4 (42–46), HR 1.2
CHD 6.0–6.4 (42–46), HR 0.8
Ischemic stroke 6.0–6.4 (42–46), HR 1.6
40 n  2213 Germans,
majority had CHD
7.5 CVD death Referent 5.5–5.9 (37–41)
5.0 (31), HR 1.42
5.0–5.4 (31–36), HR 1.29
6.0–6.4 (42–46), HR 1.35
41 n  6803 Japanese
aged 30 y
15 Referent 5.0 (31)
CVD death 5.0–5.4 (31–36), HR 1.31
5.5–5.9 (37–41), HR 1.38
6.0–6.4 (42–46), HR 2.18a
CHD death 5.0–5.4 (31–36), HR 1.20
5.5–5.9 (37–41), HR 1.46
6.0–6.4 (42–46), HR 1.11
Stroke death 5.0–5.4 (31–36), HR 1.19
5.5–5.9 (37–41), HR 1.38
6.0–6.4 (42–46), HR 2.74a
42 n  1336 Europeans and
1139 South Asians
20 European Referent 5.7 (39)
CHD 5.7–6.4 (39–46), HR 1.12
6.0–6.4 (42–46), HR 1.68a
Stroke 5.7–6.4 (39–46), HR 0.95
6.0–6.4 (42–46), HR 0.85
South Asian
CHD 5.7–6.4 (39–46), HR 0.98
6.0–6.4 (42–46), HR 1.00
Stroke 5.7–6.4 (39–46), HR 1.60
6.0–6.4 (42–46), HR 1.73a
ARIC, Atherosclerosis Risk in Communities; EPIC, European Prospective Investigation Into Cancer; HR, hazard ratio; n, number of persons followed
up (either without diabetes at baseline if those numbers provided or entire population tested if not).
a P  .05.
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ued at the end of the study in the 668 subjects who did not
have diabetes while on the drug, 48, or 7.2%, met the
OGTT criteria for diabetes when tested within 1–2 weeks
(60). Similarly, other drugs, such as acarbose (61), trogli-
tazone (62), and rosiglitazone (63) have also been effective
in delaying the development of diabetes in people with
IGT. However, within a very short period of time after
discontinuing these drugs, the incidence rates of develop-
ing diabetes were the same as the rates in those who had
received the placebo. This strongly suggests that these
drugs do not affect the intrinsic rate of glycemic rise in an
individual but simply treat the prevailing glucose levels
delaying the time that these individuals will cross the line
to values that meet the diagnostic criteria of diabetes. Be-
cause initiation of drug therapy (usuallymetformin) is rec-
ommended when diabetes is diagnosed (64), does this not
simply lower thediagnostic cutpointofdiabetes?Whether
the diagnostic cut point should be lowered requires much
public discussion and scientific justification, which has
not to our knowledge occurred.
Of note, even if no interventions are initiated in people
with prediabetes or if diabetes develops despite them,
HbA1c levels just above the threshold for diabetes (6.5%
[48mmol/mol] through 6.9% [52mmol/mol])may not be
clinically deleterious. Two randomized control trials (65,
66) and three observational studies (67–69) have clearly
demonstrated that if HbA1c levels are kept below 7.0%
(53 mmol/mol) in diabetic patients, there is no develop-
mentorprogressionof themicrovascular complicationsof
diabetes. Thus, from a clinical perspective, identifying
asymptomatic people with an FPG between 110 and 125
mg/dL (6.1–6.9 mmol/L) or an HbA1c of 6.0%–6.4%
(42–48mmol/mol) is not at all too late topreventdiabetes-
related complications, even if treatment (70) commenced
only upon the diagnosis of diabetes.
Figure 2. Relationship of the upper and lower bounds of the criteria
for prediabetes on the development of diabetes. Fold increase was the
risk of developing diabetes in individuals meeting the higher bounds
(FPG, 110–125 mg/dL [6.1–6.9 mmol/mol]; HbA1c, 6.0%–6.4% [42–
48 mmol/mol]) divided by the lower bounds (FPG, 100–109 mg/dL
[5.6–6.0 mmol/L]; HbA1c, 5.5%–5.9% [37–41 mmol/mol]) of the
criteria for diagnosing prediabetes.
Table 3. Effect of Subdiabetic Hyperglycemia (Glucose Concentrations, FPG, mg/dL [mmol/liter]) on Development
of Diabetes
Reference Population Follow-Up, y Outcome Results
27 n  2789 Chinese, Malay and Asian
Indian males
8 Developing diabetes/8 y, %
Criteria: OGTT or Rx for diabetes
100–109 (5.6–6.0), 22.2
110–125 (6.1–6.9), 55.2
30 Framingham Offspring
n  3634
4 Developing diabetes/4 y, % Women Men
Criteria: FPG 126 (7.0) or Rx with OHA
or insulin
100 (5.6) 0.3 0.6
100–109 (5.6–6.0) 4.0 4.5
110–125 (6.1–6.9) 27.8 20.0
46 Mayo Clinic
n  7408
9 Developing diabetes/9 y, % 100 (5.6), 6.7
Criterion: FPG 126 (7.0) 100–109 (5.6–6.0), 18.5
110–125 (6.1–6.9), 38.6
47 Hoorn Study
n  1342
Dutch aged 50–75 y
6.4 Developing diabetes/6.4 y, % 100 (5.6), 5
Criterion: OGTT 100–109 (5.6–6.0), 14
110–125 (6.1–6.9), 44
48 DESIR Study
n  2276 women and 2176 men
aged 30–64 y
6 Incidence/1000 person-years Women Men
Criteria: FPG 126 (7.0) or Rx with OHA 100 (5.6) 0.7 1.8
100–109 (5.6–6.0) 6.2 5.7
110–125 (6.1–6.9) 54.7 43.2
49 n  5452 6.1 Developing diabetes/y, % 100–109 (5.6–6.0), 1.34
Criteria: ICD-9 code, FPG 126 (7.0) or
Rx with OHA or insulin
110–125 (6.1–6.9), 5.16
50 n  449
Japanese aged 23–65 y
5 Developing diabetes/y, %
Criteria: FPG 126 (7.0) or clinically
treated diabetic
100 (5.6), 0.1
100–109 (5.6–6.0), 2.0
110–125 (6.1–6.9), 6.9
(independent of HbA1c levels)
51 n  6804
Japanese men aged 40–55 y
4 Developing diabetes/4 y, 100 (5.6), 2.8
Criteria: FPG 126 (7.0) or Rx
with OHA or insulin
100–109 (5.6–6.0), 11.1
110–125 (6.1–6.9), 42.1
DESIR, Data from an Epidemiological Study on the Insulin Resistance Syndrome; ICD-9, International Classification of Diseases, ninth revision; n,
number of persons followed up (either without diabetes at baseline if those numbers provided or entire population tested if not); OHA, oral
hypoglycemic agent; Rx, treatment.
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Recommendations
Given theweakness of the evidence that the glycemia of
prediabetes is a risk factor for incident CVD, especially in
those diagnosed by the lowerADAbound criteria, and the
4-fold increased risk of developing diabetes in people
meeting the upper bounds of the ADA’s criteria for the
diagnosis of prediabetes compared with the lower bound,
we strongly recommenddefiningprediabetes as FPG levels
of 110–125 mg/dL (6.1–6.9 mmol/L) or HbA1c levels of
6.0%–6.4% (42–48mmol/mol), the criteria suggested by
theWHO, the Invited Expert Panel, and the International
Expert Committee.
Given that prediabetes does not appear to be a signif-
icant risk factor for CVD and there is amuch lower risk of
developingdiabetes atFPG levelsof100–109mg/dL (5.6–
6.0 mmol/L) or HbA1c levels of 5.5%–5.9% (37–41
mmol/mol), we recommend that scarce public and health
plan resources available for the prevention of diabetes be
directed only toward people with a FPG of 110–125
mg/dL (6.1–6.9 mmol/L) or an HbA1c of 6.0%–6.4%
(42–48mmol/mol). In this time inwhich the cost of health
care continues to rise, occupies a major portion of Ame-
rica’s gross domestic product, and there is intense com-
petition for funds to combat already established acute and
chronic diseases, lifestyle interventions should be pro-
vided (via government or health plan funded programs)
only to those closer to the diagnostic criteria for diabetes.
As has been said, economic efficiency (12) dictates that
interventions are warranted when there is the greatest
chance of delaying the development of diabetes.
Finally, individuals who havemild hyperglycemia (as
defined above) could be referred to a lifestyle modifi-
cation program in which the cost is borne by the indi-
vidual participant. Given that there is no evidence that
diabetes can be delayed or that clinically meaningful
weight loss can be maintained in a community-based
program (71, 72), asking the public to fund such an
Table 4. Effect of Subdiabetic Hyperglycemia (HbA1c Levels, % [mmol/mol]) on Development of Diabetes
Reference Population Follow-Up, y Outcome Results
23 ARIC Study
n  11 092
14 Developing diabetes/14 y, % Referent 5.0 to 5.5 (31–37)
Criteria: self-reported diagnosis or use of diabetic medications 5.0 (31), 0.5
5.5 to 6.0 (37–42), 2.44
6.0 to 6.5 (42–48), 9.20
38 Women’s Health Study
n  26 443 aged 45 y
10.1 Incidence/1000 person-years
Criterion: self-report
Referent 5.0 (31)
5.0–5.4 (31–36), RR 2.9
5.5–5.9 (37–41), RR 12.1
6.0–6.4 (42–46), RR 29.3
51 n  6804 Japanese men aged
40–55 y
4 Developing diabetes/4 y
Criteria: FPG 126 (7.0) or Rx with OHA or insulin
5.4 (36), 3.0
5.4–5.7 (36–39), 6.5
5.8–6.2 (40–44), 20.6
6.3–6.7 (45–50), 41.9
52 n  1197 veterans 3 Developing diabetes/y, %
Criteria: self-report, FPG 126 (7.0) or HbA1c 7.0 (53)
4.6–5.0 (27–31), 0.67
5.1–5.5 (32–37), 0.90
5.6–6.0 (38–42), 2.53
6.1–6.5 (43–48), 6.41
53 DESIR Study
n  2820 aged 30–65 y
6 Incidence of diabetes at 6 y
Criteria: FPG 126 (7.0) or Rx with OHA or insulin
Referent 4.5 (26)
4.5–5.0 (26–31), OR 0.9
4.5–5.5 (26–37), OR 1.5
4.5–6.0 (26–42), OR 5.0
4.5–6.5 (26–48), OR 32.7
54 n  12 375 veterans 8 Risk of developing diabetes
Criteria: ICD-9 code or Rx for diabetes
Referent 4.5 (26)
4.5–4.9 (26–30), OR 1.01
5.0–5.4 (31–36), OR 1.70
5.5–5.9 (37–41), OR 4.87
6.0–6.5 (42–48), OR 16.06
55 n  1791 Koreans 4 Developing diabetes/4 y, %
Criteria: FPG 126 (7.0) or HbA1c 6.5% (48)
5.7–5.9 (39–41), 13.3
6.0–6.4 (42–46), 45.4
56 EPIC Study
n  5735
3 Risk of developing diabetes
Criteria: self-report, Rx with diabetes medication
or HbA1c 6.5% (48)
Referent 5.0 (31)
5.0–5.4 (31–36), OR 1.6
5.5–5.9 (37–41), OR 3.3
6.0–6.4 (42–46), OR 15.6
57 n  842 aged 40–79 y 15 Risk of developing diabetes
Criteria: ongoing diabetes Rx or HbA1c 6.5% (48)
Referent 5.00–5.49 (31–36)
5.50–5.99 (37–42), HR 3.21
6.00–6.49 (42–48), HR 9.26
58 DPP
n  932 placebo subjects
3.2 Subjects developing diabetes/100 person-years
Criterion: HbA1c 6.5% (48)
5.5 (37), 0.4
5.5–5.9 (37–41), 3.6
6.0–6.4 (42–46), 21.0
ARIC, Atherosclerosis Risk in Communities; DESIR, Data from an Epidemiological Study on the Insulin Resistance Syndrome; DPP, Diabetes
Prevention Program; EPIC, European Prospective Investigation Into Cancer; HR, hazard ratio; ICD-9, International Classification of Diseases, ninth
revision; n, number of persons followed up (either without diabetes at baseline if those numbers provided or entire population tested if not); OHA,
oral hypoglycemic agent; OR, odds ratio; RR, relative risk; Rx, treatment.
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intervention (through taxes or health care premiums)
seems unwarranted.
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